Complete financial analysis of HOB Biotech Group Corp.,Ltd (688656.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HOB Biotech Group Corp.,Ltd, a leading company in the Medical – Devices industry within the Healthcare sector.
- Neo Lithium Corp. (NTTHF) Income Statement Analysis – Financial Results
- Public Joint Stock Company Mosenergo (MSNG.ME) Income Statement Analysis – Financial Results
- Crest Ventures Limited (CREST.BO) Income Statement Analysis – Financial Results
- Standard Industries Limited (SIL.NS) Income Statement Analysis – Financial Results
- BBMG Corporation (601992.SS) Income Statement Analysis – Financial Results
HOB Biotech Group Corp.,Ltd (688656.SS)
About HOB Biotech Group Corp.,Ltd
HOB Biotech Group Corp.,Ltd. operates as a in vitro diagnostic company in China and internationally. It provides diagnostic tools, such as line immune, enzyme-linked immunosorbent, and chemiluminescent paramagnetic microparticle immuno assays to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care. The company was founded in 2009 and is based in Suzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 394.41M | 320.39M | 317.71M | 221.86M | 259.13M | 201.45M | 146.32M | 111.60M |
| Cost of Revenue | 149.41M | 118.14M | 98.55M | 76.40M | 82.73M | 59.16M | 44.31M | 38.34M |
| Gross Profit | 244.99M | 202.26M | 219.16M | 145.46M | 176.39M | 142.29M | 102.01M | 73.26M |
| Gross Profit Ratio | 62.12% | 63.13% | 68.98% | 65.56% | 68.07% | 70.63% | 69.72% | 65.64% |
| Research & Development | 47.01M | 38.74M | 31.79M | 24.13M | 25.44M | 24.15M | 19.69M | 23.35M |
| General & Administrative | 11.47M | 9.89M | 9.27M | 3.78M | 10.31M | 6.83M | 4.75M | 12.74M |
| Selling & Marketing | 93.88M | 78.66M | 68.05M | 50.08M | 54.72M | 42.37M | 35.63M | 31.26M |
| SG&A | 105.57M | 88.54M | 77.32M | 53.86M | 65.03M | 49.20M | 40.38M | 44.00M |
| Other Expenses | 0.00 | 32.22M | 23.65M | 15.35M | 15.14M | -2.52M | 240.16K | 1.07M |
| Operating Expenses | 189.25M | 159.51M | 132.75M | 93.35M | 105.61M | 83.36M | 68.84M | 68.59M |
| Cost & Expenses | 338.56M | 277.64M | 231.30M | 169.75M | 188.34M | 142.52M | 113.15M | 106.93M |
| Interest Income | 1.62M | 1.10M | 959.23K | 415.65K | 555.17K | 286.04K | 53.99K | 190.60K |
| Interest Expense | 2.81M | 1.92M | 1.24M | 1.89M | 1.31M | 1.63M | 1.88M | 1.59M |
| Depreciation & Amortization | 39.52M | 37.79M | 26.03M | 16.55M | 14.27M | 10.13M | 8.24M | 5.49M |
| EBITDA | 98.67M | 86.35M | 124.90M | 83.54M | 88.98M | 59.08M | 34.34M | 11.30M |
| EBITDA Ratio | 25.02% | 25.23% | 39.40% | 37.33% | 34.08% | 32.70% | 23.47% | 10.23% |
| Operating Income | 55.84M | 47.57M | 97.52M | 65.10M | 70.05M | 49.16M | 24.59M | 3.15M |
| Operating Income Ratio | 14.16% | 14.85% | 30.70% | 29.34% | 27.03% | 24.41% | 16.80% | 2.82% |
| Total Other Income/Expenses | 782.79K | -1.09M | 1.60M | 4.98K | 3.51M | -2.45M | 240.16K | -431.14K |
| Income Before Tax | 56.63M | 46.48M | 99.13M | 65.10M | 73.56M | 46.71M | 24.83M | 4.21M |
| Income Before Tax Ratio | 14.36% | 14.51% | 31.20% | 29.35% | 28.39% | 23.19% | 16.97% | 3.77% |
| Income Tax Expense | 9.29M | 4.83M | 12.93M | 8.49M | 9.72M | 6.56M | 3.47M | -122.64K |
| Net Income | 47.33M | 41.65M | 86.19M | 56.62M | 63.84M | 40.15M | 21.35M | 4.34M |
| Net Income Ratio | 12.00% | 13.00% | 27.13% | 25.52% | 24.64% | 19.93% | 14.59% | 3.88% |
| EPS | 0.75 | 0.66 | 1.37 | 0.90 | 1.01 | 0.88 | 0.47 | 0.10 |
| EPS Diluted | 0.74 | 0.66 | 1.37 | 0.90 | 1.01 | 0.88 | 0.47 | 0.10 |
| Weighted Avg Shares Out | 63.11M | 63.06M | 63.06M | 63.06M | 63.06M | 45.63M | 45.43M | 45.43M |
| Weighted Avg Shares Out (Dil) | 63.96M | 63.06M | 63.06M | 63.06M | 63.06M | 45.63M | 45.43M | 45.43M |
Source: https://incomestatements.info
Category: Stock Reports